Doxorubicin (Adriamycin [AM]) was measured in plasma in the early distributive phase in 26 patients with different solid umors. Pharmacokinetic parameters were calculated during first and/or subsequent courses of AM injected iv at doses from 0 to 60 mg/m 2 either alone or with other antineoplastic agents. A fluorimetric technique was employed to determine AM eqivalents; the reduced metabolite Adriamycinol was quantitated by scanning fluorescence after separation in thin-layer chrmatography. The following conclusions are drawn from the findings. (a) After repeated AM treatments the individual variabiliy in pharmacokinetic parameters of the drug did not appear to be affected by the length of treatment. (b) When the same ptient was given different AM doses over a certain priod some degree of dose dependence was seen only in the area under th curve and extrapolated plasma drug concentration at Time 0. (c) A narrow range of AM doses gave pharmacokinetic values diffring from one patient to another. (d) After repeated AM treatments, Adriamycinol levels became lower, suggesting either areduced metabolism of the parent compound or increased excretion of the reduced metabolite.
|Number of pages||10|
|Journal||Cancer Treatment Reports|
|Publication status||Published - 1980|
ASJC Scopus subject areas
- Cancer Research